Alcohol peptide interactions
Summary
| Peptide | Interaction | Direction | Confidence |
|---|---|---|---|
| Retatrutide | GLP-1/GIP/glucagon agonist | Flattened/delayed BAC; blunted reward | High (mechanistic); Retatrutide-specific: medium |
| BPC-157 | Gastroprotection | Hepatoprotective + gastroprotective | High (preclinical) |
| TB-500 | Hepatoprotection | Anti-inflammatory + anti-oxidant + anti-fibrotic | High (preclinical) |
| GHK-Cu | Antioxidant protection | NOT Fenton risk; anti-inflammatory | High (contradicts brief concern) |
Retatrutide {#retatrutide}
Mechanistic basis (from GLP-1RA literature)
- Gastric emptying: GLP-1 agonists slow gastric emptying → alcohol absorbed more slowly from upper intestine → flatter, delayed BAC curve → lower peak intoxicating effect
- Reward modulation: GLP-1R activation in VTA and nucleus accumbens reduces alcohol-induced dopamine release → blunted reward
- Human evidence: retrospective cohorts on GLP-1RAs less likely to develop AUD; less hospitalisation for acute alcohol intoxication
Retatrutide-specific concerns
- Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) — gastric emptying effect likely greater than semaglutide
- Glucagon agonism: alcohol already impairs hepatic gluconeogenesis; Reta’s glucagon agonism may compound hypoglycaemia risk
- Semaglutide half-life ~7 days; Retatrutide similar — interaction is continuously present, not avoidable by timing
- No specific Retatrutide-alcohol PK trial exists
Net effect: positive for reduction goals
GLP-1RAs reduce alcohol consumption and reward — consistent with Retatrutide goals for weight/ metabolic management
BPC-157 {#bpc-157}
Evidence
- Gastric lesions: BPC-157 prevents, attenuates, and reverses gastric lesions in chronic alcohol-drinking rats — across prophylactic, concurrent, and therapeutic protocols
- Liver protection: protects liver from alcohol-induced damage; reverses alcohol-induced portal hypertension
- Mechanism: free radical scavenger; normalises NO and MDA; modulates prostaglandins, dopamine, serotonin; activates VEGFR2-AKT-eNOS endothelial protection pathway
Application
- May mitigate alcohol-induced gastric and hepatic damage
- Timing: likely beneficial if taken around drinking
- Confidence: high (preclinical); no human hangover trial
TB-500 (Thymosin β4) {#tb-500}
Evidence (mouse model, IP injection)
TB-500 at 1 mg/kg for 1 week prevents ethanol- and LPS-induced liver injury via:
- Anti-oxidant: ↓ ROS, ↓ lipid peroxidation, ↑ glutathione, ↑ SOD
- Anti-inflammatory: blocks NFκB activation, ↓ pro-inflammatory cytokines
- Anti-fibrotic: suppresses MeCP2, reverses PPAR-γ suppression, downregulates fibrogenic genes
Application
- Strong mechanistic rationale for hepatoprotection
- Preclinical only — no human alcohol/liver trial
- The NF-κB pathway blocked by TB-500 is the same pathway driving hangover inflammation
GHK-Cu {#ghk-cu}
The theoretical concern (from brief)
“Copper peptide + alcohol hepatotoxicity. CYP2E1 induction by alcohol generates ROS; copper can catalyse Fenton reactions. Theoretical concern — needs investigation.”
Reality: NOT a concern
- GHK’s copper(II) is chelated and redox-silenced — does NOT participate in Fenton chemistry
- GHK-Cu is anti-oxidant, not pro-oxidant
- Prevents lipid peroxidation by binding acetaldehyde breakdown products (acrolein, 4-HNE)
- Anti-inflammatory; upregulates antioxidant genes
Application
GHK-Cu is safe to use with alcohol; likely mildly protective rather than harmful.